Wrong-subtype treatment
Lewy body, vascular, and frontotemporal dementia are still treated as if they were typical Alzheimer’s disease, which can add harm.
Overview
Antipsychotics in Lewy body disease, antibodies without amyloid confirmation, and cholinesterase inhibitors pushed in FTD are examples of map failures, not just knowledge gaps.
- Overlapping symptoms.
- Limited access to specialist assessment.
- Trial evidence dominated by Alzheimer’s disease.
- NICE NG97 pathway language.
- Lewy body awareness materials.
Similar pages
not linked directly; found by shared links- TermMixed dementia
Shares Mixed dementia, Dementia (umbrella) and the tag dementia-atlas.
- TechnologyBrain MRI
Shares Vascular dementia, Alzheimer’s disease and the tag dementia-atlas.
- BottleneckTrial populations that skip mixed disease
Shares Mixed dementia, Alzheimer’s disease and the tag dementia-atlas.
- BottleneckLate and uneven diagnosis
Shares Dementia (umbrella), Alzheimer’s disease and the tag dementia-atlas.
- TargetTDP-43
Shares Frontotemporal dementia and the tag dementia-atlas.
- TargetTau
Shares Frontotemporal dementia, Alzheimer’s disease and the tag dementia-atlas.
- DiagnosisParkinson’s disease dementia
Shares Dementia with Lewy bodies, Dementia (umbrella) and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Mixed dementia, Alzheimer’s disease and the tag dementia-atlas.